Who
Argeris N. Karabelas
Director
Company insider
Files Form 4 as: Director, Regenxbio; Director, Bausch Health Companies; Director and 10% owner, Rocket Pharmaceuticals; Chairman, Human Genome Sciences; Chairman of the Board, Vanda Pharmaceuticals; 10% owner, Biodelivery Sciences International; Chairman, Interim CEO & Pres., Nitromed.
In numbers
- Trades disclosed
- 148
- Buys
- 3
- Sells
- 32
- Bought
- $3.9M
- Sold
- $75.6M
- Companies
- 7
- Companies where not an officer
- 4
- First trade
- 20 Mar 2006
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,815 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —7,768 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.76 | filing |
| 1 Oct 2024filed 2 Oct 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $101K10,000 at $10.11 | filing |
| 3 Sep 2024filed 4 Sep 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 3 Sep 2024filed 4 Sep 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.76 | filing |
| 3 Sep 2024filed 4 Sep 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $107K9,300 at $11.50 | filing |
| 3 Sep 2024filed 4 Sep 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $8,638700 at $12.34 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —100 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $38K10,000 at $3.76 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $1,274100 at $12.74 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $129K9,600 at $13.45 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $5,836400 at $14.59 | filing |
| 1 Aug 2024filed 5 Aug 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $1,500100 at $15.00 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026Contrasting Cue Biopharma (NASDAQ:CUE) & REGENXBIO (NASDAQ:RGNX)RGNX · dailypolitical.com · 8 Oct 2026Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityRCKT · proactiveinvestors.com · 7 Oct 2026
0 headlines in the last 90 days name Argeris N. Karabelas; 5 articles from the last 14 days about the 4 companies they traded most, at most three about any one of them.